Delta 9 Cannabis Inc
SWB:V5D1
Delta 9 Cannabis Inc
SWB:V5D1
Price:
0.0072
EUR
Market Cap:
€2.2m
Relative Value
There is not enough data to reliably calculate the relative value of V5D1.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
V5D1
Relative Value
Base Case
Not Available
Multiples Across Competitors
V5D1 Competitors Multiples
Delta 9 Cannabis Inc Competitors
Delta 9 Cannabis Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Delta 9 Cannabis Inc
SWB:V5D1
|
3.5m EUR | 0 | -0.2 | -36.3 | -2.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
952.7B USD | 14.6 | 46.2 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
584.1B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
268.8B CHF | 4.4 | 20.8 | 12.2 | 13.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228.1B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.8B CHF | 5.4 | 21.6 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2.5 | 17.3 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
